. Chemokines are induced in the infarcted myocardium and may play a role in inflammatory leukocyte infiltration, fibrous tissue deposition, and cardiac repair. Monocyte Chemoattractant Protein (MCP)-1, a potent mononuclear cell chemoattractant is rapidly upregulated in infarcts and may contribute to infarct healing. The CXC chemokine Interferon-gamma inducible Protein (IP)-10, a weak mononuclear cell chemoattractant, but potent angiostatic agent with anti-fibrotic properties, is markedly induced in the infarcted heart and may have a role in regulating infarct angiogenesis and fibrosis. This proposal will examine the role of MCP-1 and IP-10 in healing myocardial infarcts.
Specific aim 1 will elucidate the functional role of MCP-1 in infarct healing, using gene-targeted animals in a murine model of myocardial infarction. MCP-1 may affect hematopoietic cells (predominantly mononuclear cells) as well as resident myocardial cells (fibroblasts and endothelial cells). In order to examine the relative importance of MCP-1 signaling in resident and blood-derived cells of the infarct, animals deficient in CCR2, the MCP-1 receptor, will be used to create chimeric mice after adoptive transfer of WT or CCR2 -/- bone marrow cells. In order to dissect the mechanisms responsible for suppressed macrophage activation and cytokine expression in the infarct we will test two intriguing hypotheses: a) that MCP-1 selectively recruits a specific monocvte subset [identified as CCR2 hi/fraktalkine receptor (CX3CR1) lo] that is more responsive to activation by inflammatory mediators, and b) that MCP-1 may directly regulate macrophage activation, differentiation and gene expression. These questions will be addressed using in vivo experiments with CX3CR1GFP/+ mice (in which GFP expression determines two distinct monocyte subpopulations in the bloodstream) and in vitro studies with isolated murine monocytes and macrophages.
Specific aim 2 will investigate the role of IP-10 in healing mvocardial infarcts. Preliminary experiments suggest that IP-10 may be less important as a leukocyte chemoattractant. but may have a crucial role in preventing premature fibroblast accumulation and angiogenesis before the infarcted area is debrided and a fibrin-based provisional matrix, necessary to support fibrous tissue deposition is formed. This hypothesis will be tested using IP-10 and CXCR3 deficient mice; in addition the relative importance of IP-10/CXCR3 interactions in resident and hematopoietic cells infiltrating the infarct will be examined using chimeric mice with adoptive transfer of WT and CXCR3 -/- bone marrow cells.
Specific aim 3 will explore the mechanisms responsible for the opposing effects of MCP-1 and IP-10 on fibrous tissue deposition using isolated cardiac fibroblasts and infarct myofibroblasts. The effects of MCP-1 and IP-10 on proliferation, migration and activation of cardiac fibroblasts and infarct myofibroblasts will be studied. Infarct myofibroblasts will be isolated from mice with defective MCP-1 (CCR2 and MCP-1 KO) and IP-10 (CXCR3 and IP-10 KO) signaling: their phenotvpe, motilitv, proliferative activity and gene expression will be compared with WT infarct myofibroblasts. Using gene microarray analysis, we identified novel actions of IP-10 in repression of genes associated with fibroblast adhesion, proliferation and migration. Accordingly we will study the effects of IP-10 on focal adhesion assembly and disassembly, fibroblast migration and proliferation. Understanding the role of chemokines in infarct healing may identify novel therapeutic targets aiming at optimizing cardiac repair and decreasing adverse remodeling.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL076246-01A2
Application #
6976794
Study Section
Myocardial Ischemia and Metabolism Study Section (MIM)
Program Officer
Massicot-Fisher, Judith
Project Start
2005-06-06
Project End
2010-04-30
Budget Start
2005-06-06
Budget End
2006-04-30
Support Year
1
Fiscal Year
2005
Total Cost
$300,000
Indirect Cost
Name
Baylor College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Chen, Bijun; Frangogiannis, Nikolaos G (2018) The Role of Macrophages in Nonischemic Heart Failure. JACC Basic Transl Sci 3:245-248
Kirk, Jonathan A; Frangogiannis, Nikolaos G (2018) Galectin-3 in the pathogenesis of heart failure: a causative mediator or simply a biomarker? Am J Physiol Heart Circ Physiol 314:H1256-H1258
Shinde, Arti V; Su, Ya; Palanski, Brad A et al. (2018) Pharmacologic inhibition of the enzymatic effects of tissue transglutaminase reduces cardiac fibrosis and attenuates cardiomyocyte hypertrophy following pressure overload. J Mol Cell Cardiol 117:36-48
Frangogiannis, Nikolaos G (2018) Cell biological mechanisms in regulation of the post-infarction inflammatory response. Curr Opin Physiol 1:7-13
Huang, Shuaibo; Frangogiannis, Nikolaos G (2018) Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges. Br J Pharmacol 175:1377-1400
Alex, Linda; Frangogiannis, Nikolaos G (2018) The Cellular Origin of Activated Fibroblasts in the Infarcted and Remodeling Myocardium. Circ Res 122:540-542
Frangogiannis, Nikolaos G (2018) Cell therapy for peripheral artery disease. Curr Opin Pharmacol 39:27-34
Kong, Ping; Shinde, Arti V; Su, Ya et al. (2018) Opposing Actions of Fibroblast and Cardiomyocyte Smad3 Signaling in the Infarcted Myocardium. Circulation 137:707-724
Shinde, Arti V; Humeres, Claudio; Frangogiannis, Nikolaos G (2017) The role of ?-smooth muscle actin in fibroblast-mediated matrix contraction and remodeling. Biochim Biophys Acta Mol Basis Dis 1863:298-309
Hanif, Waqas; Alex, Linda; Su, Ya et al. (2017) Left atrial remodeling, hypertrophy, and fibrosis in mouse models of heart failure. Cardiovasc Pathol 30:27-37

Showing the most recent 10 out of 89 publications